Dutasteride/tamsulosin
Combination of | |
---|---|
Dutasteride | 5α-Reductase inhibitor |
Tamsulosin | Alpha-1 blocker |
Clinical data | |
Trade names | Jalyn |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number |
|
KEGG |
Dutasteride/tamsulosin, sold under the brand name Jalyn among others, is a medication produced by GlaxoSmithKline for the treatment of adult male symptomatic benign prostatic hyperplasia (BPH). It is a combination of two previously existing medications: dutasteride, brand name Avodart, and tamsulosin, brand name Flomax. It contains 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride.[1]
Jalyn was the result of the CombAT (Combination of Avodart and Tamsulosin) trial of 2008. It was approved by the U.S. Food and Drug Administration (FDA) on June 14, 2010.[2] In June 2011, the FDA approved a label change warning of "Increased Risk of High-grade Prostate Cancer" from Jalyn.[3]
References[]
- ^ a b "Jalyn- dutasteride and tamsulosin hydrochloride capsule". DailyMed. Retrieved 28 December 2020.
- ^ http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022460Orig1s000Approv.pdf
- ^ https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm262877.htm[dead link]
External links[]
- "Dutasteride mixture with tamsulosin". Drug Information Portal. U.S. National Library of Medicine.
Categories:
- Drugs not assigned an ATC code
- Combination drugs
- GlaxoSmithKline brands
- Prostate disorders